The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has granted breakthrough remedy designation to sofetabart mipitecan for grownup sufferers with platinum-resistant epithelial ovarian,...
The U.S. Meals and Drug Administration (FDA) has accepted Guardant360 CDx as a companion diagnostic to determine sufferers with BRAF V600E-mutant metastatic...
Trendy a number of myeloma therapy usually entails complicated mixture therapies, which considerably impression day by day life for sufferers and care...
Amongst sufferers with high-risk melanoma, median five-year follow-up information from the part 2b KEYNOTE-942/mRNA-4157-P201 research confirmed {that a} mixture of the individualized...
